141 related articles for article (PubMed ID: 11045894)
1. Comparative pharmacological study of ropinirole (SKF-101468) and its metabolites in rats.
Reavill C; Boyfield I; Coldwell M; Nelson P
J Pharm Pharmacol; 2000 Sep; 52(9):1129-35. PubMed ID: 11045894
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
Coldwell MC; Boyfield I; Brown T; Hagan JJ; Middlemiss DN
Br J Pharmacol; 1999 Aug; 127(7):1696-702. PubMed ID: 10455328
[TBL] [Abstract][Full Text] [Related]
3. D-512, a novel dopamine D
Lindenbach D; Das B; Conti MM; Meadows SM; Dutta AK; Bishop C
Br J Pharmacol; 2017 Sep; 174(18):3058-3071. PubMed ID: 28667675
[TBL] [Abstract][Full Text] [Related]
4. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
Maggio R; Scarselli M; Novi F; Millan MJ; Corsini GU
J Neurochem; 2003 Nov; 87(3):631-41. PubMed ID: 14535946
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
[TBL] [Abstract][Full Text] [Related]
6. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
Millan MJ; Iob L; Péglion JL; Dekeyne A
Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
[TBL] [Abstract][Full Text] [Related]
7. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors.
Perachon S; Schwartz JC; Sokoloff P
Eur J Pharmacol; 1999 Feb; 366(2-3):293-300. PubMed ID: 10082211
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
[TBL] [Abstract][Full Text] [Related]
9. Effects of ropinirole on motor behavior in MPTP-treated common marmosets.
Fukuzaki K; Kamenosono T; Kitazumi K; Nagata R
Pharmacol Biochem Behav; 2000 Sep; 67(1):121-9. PubMed ID: 11113491
[TBL] [Abstract][Full Text] [Related]
10. Characterization of unconditioned behavioral effects of dopamine D3/D2 receptor agonists.
Geter-Douglass B; Katz JL; Alling K; Acri JB; Witkin JM
J Pharmacol Exp Ther; 1997 Oct; 283(1):7-15. PubMed ID: 9336302
[TBL] [Abstract][Full Text] [Related]
11. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
[TBL] [Abstract][Full Text] [Related]
12. Differential ability of D1 and D2 dopamine receptor agonists to induce and modulate expression and reinstatement of cocaine place preference in rats.
Graham DL; Hoppenot R; Hendryx A; Self DW
Psychopharmacology (Berl); 2007 Apr; 191(3):719-30. PubMed ID: 16835769
[TBL] [Abstract][Full Text] [Related]
13. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
Dhir A; Kulkarni SK
Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
[TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Vivo Identification of Novel Positive Allosteric Modulators of the Human Dopamine D2 and D3 Receptor.
Wood M; Ates A; Andre VM; Michel A; Barnaby R; Gillard M
Mol Pharmacol; 2016 Feb; 89(2):303-12. PubMed ID: 26655303
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic profile of ropinirole in the rat, mouse and common marmoset.
Rogers DC; Costall B; Domeney AM; Gerrard PA; Greener M; Kelly ME; Hagan JJ; Hunter AJ
Psychopharmacology (Berl); 2000 Jul; 151(1):91-7. PubMed ID: 10958122
[TBL] [Abstract][Full Text] [Related]
16. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
[TBL] [Abstract][Full Text] [Related]
17. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
18. The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
Wang Y; Bouabid S; Darvas M; Zhou FM
Exp Neurol; 2020 Nov; 333():113427. PubMed ID: 32735872
[TBL] [Abstract][Full Text] [Related]
19. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
20. Chronic D
Tremblay M; Silveira MM; Kaur S; Hosking JG; Adams WK; Baunez C; Winstanley CA
Eur J Neurosci; 2017 Jan; 45(1):159-166. PubMed ID: 27422144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
